Rokshaw announces the exclusive UK manufacture and distribution of medical cannabis products under the Four20 Pharma brand. Rokshaw has expanded its range of medical cannabis to meet market growth and patient demand, offering Four20 Pharma products for private prescription in the UK. Four20 Pharma, originating from Germany, has a portfolio of high-quality strains and terpene profiles that are EU-GMP approved. Rokshaw ensures consistent supply by handling the manufacture and distribution of these products. The Four20 Pharma range is now available for all doctors listed on the specialist register. Jonathan Hodgson, CEO of Rokshaw, says the company is excited to bring the Four20 Pharma range to the UK and believes it is a premium category of treatment. Richard Hodgson, Managing Director of Rokshaw, states that the Four20 Pharma range offers high-quality medical cannabis treatment that is unmatched in the current UK market. For more information, pharmacists and healthcare professionals can visit the medical cannabis page or contact [email protected]. Interested patients can visit Curaleaf Pharmacy. Rokshaw, part of Curaleaf International, is a leading expert in medical cannabis manufacture and distribution in the UK. They have a state-of-the-art UK MHRA approved manufacturing facility and work with partners to widen patient access. Their partner range, combined with their own UK-manufactured products, provides a wide variety of treatment options for specialist doctors.

Rokshaw Announces Exclusive UK Manufacture and Distribution of Medical Cannabis Products Under Four20 Pharma Brand

Opens in a new windowrokshaw.co.uk

Rokshaw Laboratories

Rokshaw Laboratories, a leading UK-based manufacturer and distributor of medical cannabis, has today announced the exclusive UK manufacture and distribution of medical cannabis products under the Four20 Pharma brand. This is a significant development for the UK medical cannabis market, as it will give patients access to a wider range of high-quality products.

Four20 Pharma is a German-based company that produces a range of high-quality medical cannabis products. The company’s products are cultivated in accordance with EU-GMP standards and are subject to rigorous testing to ensure their safety and efficacy.

Under the agreement, Rokshaw will manufacture and distribute Four20 Pharma’s products to UK pharmacies and clinics. The company will also provide support to healthcare professionals who are prescribing medical cannabis to their patients.

The launch of the Four20 Pharma range is expected to further expand Rokshaw’s position as a leading provider of medical cannabis in the UK. The company is committed to providing patients with access to high-quality, affordable medical cannabis products.

CEO of Rokshaw Jonathan Hodgson said:

Opens in a new windowmubi.com

Jonathan Hodgson

“We are delighted to announce our exclusive partnership with Four20 Pharma to manufacture and distribute their products in the UK. Four20 Pharma is a highly respected company with a proven track record of producing high-quality medical cannabis products. We are confident that their products will be well-received by patients and healthcare professionals in the UK.”

Managing Director of Rokshaw Richard Hodgson said:

Opens in a new windowwikipedia.org

Richard Hodgson

“The launch of the Four20 Pharma range is an important milestone for Rokshaw. We are committed to providing patients with access to the best possible medical cannabis products, and we believe that Four20 Pharma’s products will make a significant contribution to the UK medical cannabis market.”

The Four20 Pharma range is now available to UK patients with a private prescription.

About Rokshaw Laboratories

Rokshaw Laboratories is a leading UK-based manufacturer and distributor of medical cannabis. The company is part of Curaleaf International, the world’s largest cannabis company. Rokshaw is committed to providing patients with access to safe, effective, and affordable medical cannabis products.

About Four20 Pharma

Four20 Pharma is a German-based company that produces a range of high-quality medical cannabis products. The company’s products are cultivated in accordance with EU-GMP standards and are subject to rigorous testing to ensure their safety and efficacy.

This is a positive development for the UK medical cannabis market, as it will give patients access to a wider range of high-quality products. Rokshaw Laboratories is a leading provider of medical cannabis in the UK, and Four20 Pharma is a highly respected company with a proven track record of producing high-quality products. I am confident that this partnership will be beneficial for both companies and for patients in the UK.